Olaparib Outcomes in Patients with BRCA 1-2 Mutated, Platinum-Sensitive, Recurrent Ovarian Cancer in Croatia: A Retrospective Noninterventional Study

Olaparib Outcomes in Patients with BRCA 1-2 Mutated, Platinum-Sensitive, Recurrent Ovarian Cancer in Croatia: A Retrospective Noninterventional Study

Our objective was to assess the safety and efficacy of olaparib in maintenance therapy of BRCA 1-2 mutated, platinum-sensitive, recurrent ovarian carcinoma after the partial or complete response to the second or further lines platinum-based chemotherapy in a real-world setting. We performed a multic...

Full description

Bibliographic Details
Main Authors:	Ana Majić, Branka Petrić Miše, Višnja Matković, Ingrid Belac Lovasić, Kristina Katić, Ivana Canjko, Ana Frobe, Žarko Bajić, Eduard Vrdoljak
Format:	Article
Language:	English
Published:	Hindawi Limited 2020-01-01
Series:	Journal of Oncology
Online Access:	http://dx.doi.org/10.1155/2020/6423936

Similar Items

Real-World Efficacy and Safety of Bevacizumab in the First-Line Treatment of Metastatic Cervical Cancer: A Cohort Study in the Total Population of Croatian Patients
by: Dora Čerina, et al.
Published: (2021-01-01)

Zebrafish Xenografts Unveil Sensitivity to Olaparib beyond BRCA Status
by: Ana Beatriz Varanda, et al.
Published: (2020-07-01)

Olaparib is effective for recurrent urothelial carcinoma with BRCA2 pathogenic germline mutation: first report on olaparib response in recurrent UC
by: Hong Yang, et al.
Published: (2020-11-01)

Beyond BRCA Status: Clinical Biomarkers May Predict Therapeutic Effects of Olaparib in Platinum-Sensitive Ovarian Cancer Recurrence
by: Kazuho Nakanishi, et al.
Published: (2021-07-01)

Olaparib Combined with an ATR or Chk1 Inhibitor as a Treatment Strategy for Acquired Olaparib-Resistant <i>BRCA1</i> Mutant Ovarian Cells
by: Brian T. Burgess, et al.
Published: (2020-02-01)

Spotlight on olaparib in the treatment of BRCA-mutated ovarian cancer: design, development and place in therapy
by: Lorusso D, et al.
Published: (2018-05-01)

Olaparib Treatment in a Patient with Advanced Gallbladder Cancer Harboring BRCA1 Mutation
by: Li X, et al.
Published: (2021-04-01)

BRCA1 Expression and Outcome in Patients With EGFR-Mutant NSCLC Treated With Gefitinib Alone or in Combination With Olaparib
by: Niki Karachaliou, MD, PhD, et al.
Published: (2021-03-01)

Treatment with olaparib monotherapy for BRCA2-mutated refractory intrahepatic cholangiocarcinoma: a case report
by: Cheng Y, et al.
Published: (2018-09-01)

Cost-Effectiveness Analysis of Olaparib Maintenance Treatment for Germline BRCA-Mutated Metastatic Pancreatic Cancer
by: Na Li, et al.
Published: (2021-04-01)

Genomic Profile and BRCA-1 Promoter Methylation Status in BRCA Mutated Ovarian Cancer: New Insights in Predictive Biomarkers of Olaparib Response
by: Elisena Franzese, et al.
Published: (2019-11-01)

Efficacy and safety of olaparib maintenance therapy in platinum-sensitive ovarian cancer patients with BRCA mutations: a meta-analysis on randomized controlled trials
by: Ma J, et al.
Published: (2019-04-01)

Izkušnje z zdravilom olaparib pri zdravljenju recidivnega epitelijskega raka jajčnikov z mutacijami v genih BRCA 1 in BRCA 2
by: Erik Škof
Published: (2021-05-01)

Lynparza (olaparib)
by: Erik Škof, et al.
Published: (2016-06-01)

Olaparib in the maintenance treatment of platinum-sensitive relapse of BRCA mutant ovarian cancer in routine clinical practice: first results of observational study in Russian patients
by: E V Artamonova, et al.
Published: (2018-09-01)

Economic impact of olaparib on maintenance treatment of patients with BRCA-mutation positive, platinum-sensitive relapsing high-grade serous epithelial ovarian cancer in Spain
by: Luis Cordero Puentes, et al.
Published: (2018-05-01)

Response to olaparib in metastatic castration-resistant prostate cancer with germline BRCA2 mutation: a case report
by: Yi Ma, et al.
Published: (2018-10-01)

Randomised phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer (OCTOVA): a study protocol
by: Rachel Dunn, et al.
Published: (2021-01-01)

First-line treatment of advanced ovarian cancer: an expert update
by: Branka Petrić-Miše
Published: (2020-01-01)

H-Ferritin-nanocaged olaparib: a promising choice for both BRCA-mutated and sporadic triple negative breast cancer
by: S. Mazzucchelli, et al.
Published: (2017-08-01)

Combination of triapine, olaparib, and cediranib suppresses progression of BRCA-wild type and PARP inhibitor-resistant epithelial ovarian cancer.
by: Z Ping Lin, et al.
Published: (2018-01-01)

Olaparib as maintenance treatment for patients with platinum-sensitive relapsed ovarian cancer
by: Jonathan A. Ledermann, et al.
Published: (2019-05-01)

Olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer
by: S V Khokhlova
Published: (2017-09-01)

An assessment of dose indicators for computed tomography localization procedures in radiation therapy at the University Hospital Rijeka
by: Diklić Ana, et al.
Published: (2018-01-01)

Anticipating a Reverse Mortgage Adoption in Croatia
by: Ana Kundid Novokmet, et al.
Published: (2020-12-01)

Recurrent uterine serous carcinoma with a germline pathogenic BRCA2 variant treated using olaparib: A case report
by: Kayo Inoue, et al.
Published: (2020-05-01)

Olaparib in the management of ovarian cancer
by: Bixel K, et al.
Published: (2015-08-01)

Olaparib: Transcending mutational barriers
by: Abhishek Chandna
Published: (2019-01-01)

Real-World Safety and Efficacy of Nivolumab in Advanced Squamous and Nonsquamous Non-Small-Cell Lung Cancer: A Retrospective Cohort Study in Croatia, Hungary, and Malta
by: Eduard Vrdoljak, et al.
Published: (2020-01-01)

Olaparib and Pembrolizumab Treatment for BRCA1-Mutated and PD-L1-Positive Intrahepatic Cholangiocarcinoma Recurrence and Metastasis: A Case Report
by: Xiong F, et al.
Published: (2020-07-01)

Synergistic Effect of a HER2 Targeted Thorium-227 Conjugate in Combination with Olaparib in a BRCA2 Deficient Xenograft Model
by: Katrine Wickstroem, et al.
Published: (2019-10-01)

Association between Olaparib Exposure and Early Toxicity in BRCA-Mutated Ovarian Cancer Patients: Results from a Retrospective Multicenter Study
by: Maud Velev, et al.
Published: (2021-08-01)

Effects of Combined Treatment with Ionizing Radiation and the PARP Inhibitor Olaparib in BRCA Mutant and Wild Type Patient-Derived Pancreatic Cancer Xenografts.
by: Ines Lohse, et al.
Published: (2016-01-01)

Overall survival and disease control rates for operable invasive breast cancer in the era of conservative surgery; retrospective, institutional, and five-year follow-up data
by: Ana Car-Peterko, et al.
Published: (2020-01-01)

Research on user satisfaction with the quality of services in secondary education in Croatia
by: Olivera Jurković Majić
Published: (2007-12-01)

An exceptional response to olaparib in relapsed and refractory BRCA2 mutated non-small cell lung cancer in hereditary breast–ovarian cancer syndrome
by: Vikas T. Talreja, et al.
Published: (2020-01-01)

Cost-Effectiveness Analysis of Maintenance Olaparib in Patients with Metastatic Pancreatic Cancer and a Germline BRCA1/2 Mutation Based on the POLO Trial
by: Zhan M, et al.
Published: (2020-12-01)

Complete pathological response to olaparib and bevacizumab in advanced cervical cancer following chemoradiation in a BRCA1 mutation carrier: a case report
by: Rosa Montero-Macias, et al.
Published: (2021-04-01)

BKM120 sensitizes BRCA-proficient triple negative breast cancer cells to olaparib through regulating FOXM1 and Exo1 expression
by: Yu Li, et al.
Published: (2021-02-01)

The combination of olaparib and camptothecin for effective radiosensitization
by: Miura Katsutoshi, et al.
Published: (2012-04-01)